drugset / Trial / NCT05720234
Avatrombopag Combined With IST as First-line Treatment for SAA
NaSingle-groupOpen-labelTreatment
Summary
This single-center study aims to evaluate the early efficacy and safety of avatrombopag combined with immunosuppressive therapy (IST) in the first-line treatment of severe aplastic anemia (SAA).
Timeline
- Start
- 2022-11-10
- Primary completion
- 2023-11-30
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 40 mg | Oral |
| Subject | Avatrombopag | Small molecule | 60 mg | Oral |